Reparixin, an inhibitor of IL-8 receptor such as CXCR1/2, inhibits neutrophil influx, fibrogenic cytokine, and decreases pulmonary fibrosis by blocking CXCR2 [46]. The gene discussed is CXCR2; the disease is pulmonary fibrosis.